Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombectomy | 18 | 2026 | 253 | 2.450 |
Why?
|
| Stents | 20 | 2026 | 502 | 2.130 |
Why?
|
| Intracranial Aneurysm | 9 | 2026 | 384 | 2.000 |
Why?
|
| Endovascular Procedures | 12 | 2026 | 626 | 1.810 |
Why?
|
| Embolization, Therapeutic | 6 | 2024 | 334 | 1.800 |
Why?
|
| Cerebral Angiography | 8 | 2024 | 301 | 1.600 |
Why?
|
| Stroke | 13 | 2024 | 1216 | 1.440 |
Why?
|
| Aneurysm, Ruptured | 4 | 2026 | 81 | 1.230 |
Why?
|
| Carotid Stenosis | 3 | 2022 | 99 | 1.230 |
Why?
|
| Radial Artery | 4 | 2022 | 56 | 1.210 |
Why?
|
| Catheters | 6 | 2026 | 78 | 1.030 |
Why?
|
| Subarachnoid Hemorrhage | 3 | 2023 | 110 | 1.020 |
Why?
|
| Transverse Sinuses | 2 | 2022 | 6 | 0.920 |
Why?
|
| Carotid Artery, Internal | 7 | 2023 | 68 | 0.890 |
Why?
|
| Brain Ischemia | 8 | 2022 | 424 | 0.860 |
Why?
|
| Treatment Outcome | 28 | 2026 | 5822 | 0.820 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2023 | 26 | 0.780 |
Why?
|
| Mucopolysaccharidosis II | 1 | 2022 | 10 | 0.760 |
Why?
|
| Femoral Artery | 2 | 2022 | 105 | 0.750 |
Why?
|
| Central Nervous System Vascular Malformations | 5 | 2022 | 77 | 0.740 |
Why?
|
| Lithotripsy | 1 | 2022 | 10 | 0.740 |
Why?
|
| Immunoconjugates | 4 | 2026 | 96 | 0.730 |
Why?
|
| Vascular Calcification | 1 | 2022 | 26 | 0.720 |
Why?
|
| Retrospective Studies | 29 | 2026 | 6884 | 0.670 |
Why?
|
| Trastuzumab | 4 | 2023 | 20 | 0.570 |
Why?
|
| Humans | 59 | 2026 | 65554 | 0.560 |
Why?
|
| Anterior Cerebral Artery | 3 | 2026 | 11 | 0.530 |
Why?
|
| Aged | 28 | 2026 | 14958 | 0.480 |
Why?
|
| Cranial Sinuses | 3 | 2022 | 13 | 0.480 |
Why?
|
| Middle Aged | 30 | 2026 | 18277 | 0.440 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2026 | 235 | 0.430 |
Why?
|
| Aged, 80 and over | 15 | 2026 | 5620 | 0.430 |
Why?
|
| Thrombosis | 3 | 2022 | 205 | 0.420 |
Why?
|
| Female | 36 | 2026 | 34131 | 0.400 |
Why?
|
| Camptothecin | 3 | 2023 | 30 | 0.370 |
Why?
|
| Male | 33 | 2026 | 31083 | 0.360 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2025 | 87 | 0.340 |
Why?
|
| Cavernous Sinus | 1 | 2010 | 9 | 0.320 |
Why?
|
| Veins | 1 | 2010 | 64 | 0.310 |
Why?
|
| Aneurysm, False | 2 | 2022 | 51 | 0.310 |
Why?
|
| Pseudotumor Cerebri | 2 | 2018 | 11 | 0.280 |
Why?
|
| Carotid Artery Diseases | 2 | 2018 | 61 | 0.260 |
Why?
|
| Hematoma | 2 | 2024 | 82 | 0.250 |
Why?
|
| Constriction, Pathologic | 3 | 2022 | 132 | 0.240 |
Why?
|
| Adenosine Monophosphate | 1 | 2026 | 30 | 0.240 |
Why?
|
| Adult | 19 | 2026 | 17417 | 0.240 |
Why?
|
| Angiography | 4 | 2020 | 154 | 0.240 |
Why?
|
| Registries | 3 | 2026 | 904 | 0.240 |
Why?
|
| Incidence | 4 | 2022 | 1410 | 0.240 |
Why?
|
| Cerebral Revascularization | 2 | 2017 | 30 | 0.230 |
Why?
|
| Reperfusion | 1 | 2025 | 38 | 0.230 |
Why?
|
| Social Class | 1 | 2026 | 139 | 0.220 |
Why?
|
| Endarterectomy, Carotid | 2 | 2017 | 79 | 0.220 |
Why?
|
| Platelet Function Tests | 1 | 2024 | 11 | 0.210 |
Why?
|
| Moyamoya Disease | 1 | 2024 | 13 | 0.210 |
Why?
|
| Posterior Cerebral Artery | 1 | 2023 | 13 | 0.200 |
Why?
|
| Cerebral Veins | 1 | 2023 | 37 | 0.200 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2022 | 6 | 0.190 |
Why?
|
| Tinnitus | 1 | 2022 | 16 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2023 | 48 | 0.190 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2023 | 174 | 0.190 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 83 | 0.190 |
Why?
|
| Cerebral Hemorrhage | 2 | 2022 | 100 | 0.190 |
Why?
|
| Neoplasms | 2 | 2026 | 1415 | 0.190 |
Why?
|
| Maytansine | 1 | 2022 | 6 | 0.190 |
Why?
|
| Vasospasm, Intracranial | 1 | 2022 | 30 | 0.190 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 69 | 0.190 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 1229 | 0.180 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2022 | 19 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 50 | 0.180 |
Why?
|
| Carotid Arteries | 1 | 2022 | 63 | 0.180 |
Why?
|
| Phlebography | 2 | 2018 | 45 | 0.180 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2022 | 29 | 0.180 |
Why?
|
| Nerve Block | 1 | 2022 | 58 | 0.180 |
Why?
|
| Radiography, Interventional | 2 | 2022 | 82 | 0.170 |
Why?
|
| One-Lung Ventilation | 1 | 2020 | 6 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 471 | 0.160 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2023 | 226 | 0.160 |
Why?
|
| Prospective Studies | 7 | 2025 | 3355 | 0.150 |
Why?
|
| Brain | 3 | 2023 | 1606 | 0.150 |
Why?
|
| Neurosurgical Procedures | 1 | 2020 | 104 | 0.150 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2020 | 143 | 0.140 |
Why?
|
| Intracranial Hypotension | 1 | 2018 | 11 | 0.140 |
Why?
|
| Ocular Motility Disorders | 1 | 2017 | 3 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 81 | 0.130 |
Why?
|
| Workload | 1 | 2018 | 127 | 0.130 |
Why?
|
| Pneumonia | 1 | 2020 | 293 | 0.130 |
Why?
|
| Arteries | 1 | 2017 | 81 | 0.130 |
Why?
|
| Operative Time | 1 | 2017 | 93 | 0.130 |
Why?
|
| Feasibility Studies | 3 | 2025 | 582 | 0.130 |
Why?
|
| Blood Pressure | 1 | 2019 | 526 | 0.130 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 127 | 0.130 |
Why?
|
| Radiation Dosage | 1 | 2017 | 140 | 0.120 |
Why?
|
| Phantoms, Imaging | 1 | 2017 | 232 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 1672 | 0.120 |
Why?
|
| Patient Selection | 1 | 2018 | 490 | 0.120 |
Why?
|
| Japan | 2 | 2026 | 64 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2018 | 434 | 0.110 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 272 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2026 | 880 | 0.100 |
Why?
|
| Contrast Media | 1 | 2016 | 433 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2026 | 2632 | 0.100 |
Why?
|
| Neurosurgery | 1 | 2013 | 31 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 2510 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2015 | 156 | 0.100 |
Why?
|
| Computed Tomography Angiography | 3 | 2019 | 142 | 0.090 |
Why?
|
| Ultrasonic Therapy | 1 | 2012 | 9 | 0.090 |
Why?
|
| Angioplasty | 1 | 2012 | 53 | 0.090 |
Why?
|
| Physicians | 1 | 2018 | 488 | 0.090 |
Why?
|
| Embolism, Paradoxical | 1 | 2012 | 14 | 0.090 |
Why?
|
| Caregivers | 1 | 2015 | 292 | 0.090 |
Why?
|
| Eating | 2 | 2022 | 140 | 0.090 |
Why?
|
| Drainage | 2 | 2023 | 155 | 0.090 |
Why?
|
| Dura Mater | 1 | 2010 | 33 | 0.080 |
Why?
|
| Catheterization | 1 | 2010 | 113 | 0.080 |
Why?
|
| Intracranial Pressure | 2 | 2018 | 19 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 998 | 0.070 |
Why?
|
| Quality of Life | 1 | 2015 | 1270 | 0.070 |
Why?
|
| Cerebral Infarction | 2 | 2022 | 84 | 0.070 |
Why?
|
| Young Adult | 3 | 2026 | 4831 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2782 | 0.060 |
Why?
|
| Heart Failure | 1 | 2015 | 943 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 2 | 2021 | 244 | 0.060 |
Why?
|
| B7 Antigens | 1 | 2026 | 1 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 1 | 2026 | 41 | 0.060 |
Why?
|
| United States | 3 | 2026 | 8131 | 0.060 |
Why?
|
| Suction | 1 | 2025 | 34 | 0.060 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2017 | 140 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2023 | 2248 | 0.060 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2024 | 16 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2024 | 1326 | 0.050 |
Why?
|
| Mechanical Thrombolysis | 1 | 2024 | 37 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2024 | 74 | 0.050 |
Why?
|
| Sympathectomy | 1 | 2022 | 5 | 0.050 |
Why?
|
| Aspirin | 1 | 2024 | 172 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2023 | 124 | 0.050 |
Why?
|
| Subclavian Artery | 1 | 2022 | 26 | 0.050 |
Why?
|
| Cannula | 1 | 2022 | 24 | 0.050 |
Why?
|
| Dilatation | 1 | 2022 | 34 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2022 | 68 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2022 | 72 | 0.050 |
Why?
|
| Circle of Willis | 1 | 2021 | 7 | 0.040 |
Why?
|
| Adolescent | 2 | 2026 | 6377 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2023 | 303 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2023 | 487 | 0.040 |
Why?
|
| Carotid Artery, Common | 1 | 2020 | 30 | 0.040 |
Why?
|
| Everolimus | 1 | 2020 | 22 | 0.040 |
Why?
|
| Bronchi | 1 | 2020 | 85 | 0.040 |
Why?
|
| Trachea | 1 | 2020 | 84 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 39 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 103 | 0.040 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 45 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 221 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 40 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 1575 | 0.040 |
Why?
|
| Child | 2 | 2020 | 4681 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 205 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 237 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 204 | 0.040 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2018 | 31 | 0.030 |
Why?
|
| Blister | 1 | 2018 | 16 | 0.030 |
Why?
|
| Headache | 1 | 2018 | 58 | 0.030 |
Why?
|
| Models, Biological | 1 | 2023 | 1217 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2017 | 67 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 178 | 0.030 |
Why?
|
| Acute Disease | 1 | 2019 | 678 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 301 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 861 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 764 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 298 | 0.030 |
Why?
|
| Hospitals | 1 | 2018 | 391 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 878 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 2077 | 0.030 |
Why?
|
| Hypertension | 1 | 2019 | 613 | 0.030 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2013 | 17 | 0.030 |
Why?
|
| Heart Ventricles | 1 | 2015 | 267 | 0.020 |
Why?
|
| India | 1 | 2013 | 161 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2013 | 208 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 3788 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 661 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 557 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 272 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 2700 | 0.010 |
Why?
|